Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy

Intern Med. 2013;52(5):589-91. doi: 10.2169/internalmedicine.52.6632. Epub 2013 Mar 1.

Abstract

Drug-induced vessel vasculitis is a rare complication of chemotherapy. In particular, few reports have investigated drug-induced large vessel vasculitis. We herein report the case of a 57-year-old woman with advanced lung adenocarcinoma who developed perinuclear anti-neutrophil cytoplastic antibodies (p-ANCA)-positive periaortitis induced by bevacizumab combination chemotherapy. With the increasing use of combination therapy with bevacizumab, the incidence of vascular complications will potentially increase. A noninfectious fever occurring during chemotherapy might be a sign of vasculitis; therefore, we must ensure that possible periaortitis is not overlooked.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / immunology
  • Adenocarcinoma of Lung
  • Antibodies, Antineutrophil Cytoplasmic / adverse effects*
  • Antibodies, Antineutrophil Cytoplasmic / biosynthesis*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Aortitis / diagnosis*
  • Aortitis / drug therapy
  • Aortitis / immunology
  • Bevacizumab
  • Female
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / immunology
  • Middle Aged

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab